Fore Biotherapeutics has reeled in a $75 million Series D, and its CEO Matthew Ros is walking off the course for “other professional pursuits,” the Philadelphia drug developer said Wednesday morning.
Originally an Israeli diagnostics company known as Novellus, Fore made the transition to pharmaceuticals a…
Click here to view original post
